U.S. Markets closed

What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

Mike Benson
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.